Hangzhou Tigermed Consulting Co Ltd
SZSE:300347
Hangzhou Tigermed Consulting Co Ltd
Cash from Operating Activities
Hangzhou Tigermed Consulting Co Ltd
Cash from Operating Activities Peer Comparison
Competitive Cash from Operating Activities Analysis
Latest Figures & CAGR of Competitors
Company | Cash from Operating Activities | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
---|---|---|---|---|---|
Hangzhou Tigermed Consulting Co Ltd
SZSE:300347
|
Cash from Operating Activities
¥1.2B
|
CAGR 3-Years
5%
|
CAGR 5-Years
17%
|
CAGR 10-Years
31%
|
|
WuXi AppTec Co Ltd
SSE:603259
|
Cash from Operating Activities
¥13.4B
|
CAGR 3-Years
50%
|
CAGR 5-Years
52%
|
CAGR 10-Years
N/A
|
|
Pharmaron Beijing Co Ltd
SZSE:300759
|
Cash from Operating Activities
¥2.8B
|
CAGR 3-Years
19%
|
CAGR 5-Years
28%
|
CAGR 10-Years
N/A
|
|
WuXi Biologics (Cayman) Inc
HKEX:2269
|
Cash from Operating Activities
¥6.8B
|
CAGR 3-Years
54%
|
CAGR 5-Years
55%
|
CAGR 10-Years
N/A
|
|
Genscript Biotech Corp
HKEX:1548
|
Cash from Operating Activities
-$245.5m
|
CAGR 3-Years
-18%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
M
|
MGI Tech Co Ltd
SSE:688114
|
Cash from Operating Activities
¥1.4B
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
See Also
What is Hangzhou Tigermed Consulting Co Ltd's Cash from Operating Activities?
Cash from Operating Activities
1.2B
CNY
Based on the financial report for Dec 31, 2023, Hangzhou Tigermed Consulting Co Ltd's Cash from Operating Activities amounts to 1.2B CNY.
What is Hangzhou Tigermed Consulting Co Ltd's Cash from Operating Activities growth rate?
Cash from Operating Activities CAGR 10Y
31%
Over the last year, the Cash from Operating Activities growth was -15%. The average annual Cash from Operating Activities growth rates for Hangzhou Tigermed Consulting Co Ltd have been 5% over the past three years , 17% over the past five years , and 31% over the past ten years .